Marea Therapeutics · 1 day ago
Executive Director, Biostatistics
Marea Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for cardioendocrine diseases. The Executive Director of Biostatistics will lead biometrics activities related to clinical trials, ensuring alignment with corporate and regulatory standards while overseeing statistical strategies and data management.
BiotechnologyGeneticsLife Science
Responsibilities
Oversee operations and management of biometrics including statistics, statistical programming and data management
Ensure statistical strategies align with company business objectives, such as those related to trial design and conduct, regulatory submissions, and scientific publications
Define, institute, and oversee best practices regarding planning, execution, handling, and interpretation of scientific and clinical results to ensure high quality and compliant data handling and interpretation
Work cross-functionally toward strategic and creative problem-solving for statistical approaches in studies, including researching new statistical methods to support program needs that align with regulatory and industry standards
Collaborate with thought leaders and experts in the field to ensure that statistical methods and findings are in line with best practices and the latest scientific and statistical advancements
Identify, engage, and manage key biometrics vendors, consultants, and thought leaders (e.g., in statistics, programming, and data management)
Provide statistical oversight and support global regulatory strategy, planning, submissions, and interactions
Ensure strong data handling and infrastructure, including ongoing evaluation and implementation of systems and vendors
Collaborate with Clinical Operations and other teams to oversee/coordinate/support user acceptance testing (UAT) when electronic data capture (EDC) systems are being implemented for
Review and approve study database specifications, data management plans, data transfer plans, CDISC and ADaM specifications, and ensures reviews as needed by other appropriate team members
Anticipate, identify, and assist in the resolution of risks, bottlenecks, and potential issues in biometrics-related activities
Continually assess and plan for appropriate resourcing to meet approved biometrics initiatives
Provide regular updates to cross-functional and leadership teams to ensure alignment, resourcing, and tracking
Qualification
Required
PhD in statistics or related field
At least 15 years in related positions in pharmaceuticals/biotechnology, with increasing responsibility and which must include planning, analysis, and reporting of clinical trials
Proven leadership of teams and vendors including statisticians, programmers, and data managers
In-depth knowledge of all phases of the global drug development
Demonstrated ability to work in a cross-functional environment
Knowledge of global regulatory submission processes and able to provide support to the regulatory team
Strong verbal and written communication, presentation, and interpersonal skills to be effective in communicating and interacting with a diverse group of people
Superb attention to detail
Exceptional time and project management skills, with the ability to execute on plans under pressure in a small, fast-paced environment with tight deadlines
High integrity and sense of urgency, with a desire to individually contribute and lead
Highly motivated, proactive, enthusiastic, and goal orientated
Ability to anticipate potential pitfalls and proactively solve problems
Ability to work independently plus coordinate and work with large cross-functional teams
Preferred
Experience in cardiovascular, metabolic diseases, and/or rare diseases is a plus
Experience in supporting large, long-term studies and clinical development plans is a plus
Experience with supporting publications and communications strategies
Company
Marea Therapeutics
Marea is a biotechnology company that develops therapies and medications for the treatment of cardioendocrine illness patients.
Funding
Current Stage
Growth StageTotal Funding
$255.42MKey Investors
Third Rock Ventures
2024-06-18Series B· $190M
2024-06-18Series A· $65.42M
Recent News
Clinical Trials Arena
2026-01-16
2026-01-15
Company data provided by crunchbase